Andrea Cosenza, Analysis Scholar at College of Pittsburgh College of Medication, shared on LinkedIn:
“I’m thrilled to share our new paper, revealed right this moment in JAMA!
Utilizing the Nationwide Most cancers Database, we examined up to date patterns of focal remedy use in sufferers with nonmetastatic prostate most cancers identified between 2010 and 2023.
Amongst 15,672 sufferers receiving focal remedy, 51% had low-, high-, or very-high-risk illness; settings wherein routine use of focal remedy will not be supported by present tips.
These findings spotlight the significance of rigorously evaluating how focal remedy is being adopted in scientific follow whereas sturdy comparative and long-term proof continues to evolve.
Extraordinarily grateful to my mentors and all my coauthors for his or her steerage, assist, and collaboration all through this work!”
Title: Focal Remedy for Prostate Most cancers
Authors: Andrea Cosenza, David-Dan Nguyen, Zhiyu Qian, Rui Bernardino, Adam Olson, Alexander P. Cole, Benjamin J. Davies, Giorgio Gandaglia, Bruce L. Jacobs, Quoc-Dien Trinh
It’s also possible to learn: PSMAddition: [177Lu]Lu-PSMA-617 Improves Radiographic PFS in PSMA-Positive mAPMN/S Prostate Cancer
